[rhPTH(1-84)] 가

[rhPTH(1-84)] 가

2001 6

가 가

,

• ,

,

가

	1
•	5
1.	5
2.	5
3.	5
4.	6
5. CFU-Fs	6
6. ALP	6
7.	6
8.	7
9.	7
10.	····· 7
III	8
1.	8
2. CFU-Fs	ALP 10
3.	
4.	
5.	14

IV.	1	5
V.	1	8
	1	9
		. 2.

Figure 1.			
			9
Figure 2.	CFU-Fs	ALP	10
Figure 3.	CFU-Fs	ALP	11
Figure 4.			12
Figure 5.			13

1.	8
2.	14

가

bisphosphanate)가 가(potency) (genomic action) (non-genomic action) 가 가 가 7-8 가 6 dexamethasone betamethasone(dexa > beta) . 1 : , 2 : dexamethasone , 3 betamethasone , 4 : dexamethasone + rhPTH(1-84) : betamethasone + rhPTH(1-84) 가 1. 2 가 2. (mesenchymal cell) 3. CFU-Fs (pre-osteoblast) ALP(alkaline phosphatase) , 2

CFU-Fs ALP 가 . 3 ALP 가 4. (mineralization) 5. 2 가 5 (histomorphometry) 2 6. (trabecular bone) 가 5 가 dexamethasone betamethasone 가 ALP (mesenchymal mineralization cell) (pre-osteoblast) (accumulation) in vivo 가 dexamethasone (osteocyte) (apoptosis) dexamethasone 가

,

```
Ι.
                                       가
 (anti-inflammatory)
                  {\sf mRNA}
                                 (genomic action)
                                (non-genomic action)
Buttgereit
                   가
                    가(potency)
                  prednylidene
                                  prednisolone
    가
                   , prednisolone
                                           8
    가
                   , dexamethasone
                                      betamethasone
          가
                                       dexamethasone
            (
                : dexamethasone)
                                       가
                  가
                                                         (osteoblast)
                                                               가
            (osteoclast)
                 가
.<sup>5-9</sup>
                  10-11
Jilka
                                        (osteoblastogenesis)
                                     (early apoptosis)
```

```
(apoptosis)
                    가
                                                            가
                                                        가
                        (PTH)
      , 1998
              Lane
                        1
51
                       1 400 U(25 μg)
                                         11 ± 1.4 %(DXA)
                          150 %
      가,
                                    가 가
  19-21
          Turner
                     가
22
                                       가
                                                           가
                                                       가
             가
                                       23-24
                 , fluoride, bisphosphonates, thiazide, anabolic
D
                               14-18
                                          가
   가
                                                  가
                                  (mesenchymal cell)
                                 가
        가
                                                   가
                        25
    (prednisolone
                      2.1 mg/kg/d)
                                            26
            3-4
                                                            가
          dexamethasone
                          betamethasone
```

4

1.

```
ICR mouse 37
                                30-35g)
                                      1
                                                      (control
group, Control, n=5)
                                                           2
  dexamethasone
                      (Dexa, n=8) 0.3 mg/kg
                                                          32
                      3 betamethasone
                                                  (Beta, n=8)
                         32
   0.3 mg/kg
                                                  4 2
      dexamethasone
                                                   150 μg/kg
                  (Dexa + PTH , n=8),
                                           5
betamethasone
                                            150 \mug/kg
         . (Beta + PTH, n=8)
2.
               32
1)
                                                    5
(betamethasone 21-phosphate , dexamethasone disodium-phosphate
  Sigma
                      .)
                                   (rhPTH(1-84)]
2) 4
        5
                                                   32
             5
                        (rhPTH(1-84)
                .)
3.
32
ketamine
                                         (dual energy X-ray
absorptiometry, DXA, Hologic QDR-4500A, small animal program,
Waltham, MA, U.S.A)
```

5

4.				
	2			PBS
serum(FBS)	37 , 5% CO -MEN	02 incubator	10% feta 2	l bovine
5. CFU-Fs (colony	forming unit-	fibroblasts)		
crystal v ethanol + ammoniu ,	iolet working	thanol solution(crys 1: 10) 7	•	PBS PBS 0-95%) :
6. ALP(alkaline p	hosphatase)			
ALP kit(No. 85L-solution . 48ml diazonium salt	acetone 2	AS-MX phosph	30 Iue RR salt c	solution
	red violet	nuclear sta 50	ining	가
7.				
			von Kossa	

6

sodium thiosulphate(2.5 g/100 ml)

PBS

1% AgNO3(1% AgNO3 : 1 g/100 ml)

ethanol 30 5

2.5%

```
8.
                       secondary spongiosa
Hematoxylin & Eosin
9.
                          (Histomophometry)
                                                               Pixel
                    sample
digital analysis program (
   pixel
                          pixel
                                                               , 1
pixel
                       pixel
          1990
                  Podenpahnt 1  
                                  Denish Medical Bulletin
             . 27
      (cortical bone)
               , Cortical tissue area(cor area) :
            , Cortical mineralized bone area(cor min area) :
                              (pore)
           , Corrected cortical width(CCW) :
                                                           /
              , Cortical porosity (Cor por) :
       x 100%
      (trabecular bone)
         , Trabecular bone volume(TBV) :
                                                       /
            x 100%
                 , Mean trabecular plate thickness(MTPT) :
    x2/
10.
                               t-test
                       (ANOVA)
   0.05
```

1.

지 기 가 기 기 4

(1, Figure 1).

1.

Group	Initial Wt.(g)	Last Wt.(g)	Area(cm ²)	BMC(g)	BMD (cm ² /g)
1	31.95	35.46	10.82	0.87	0.081
(Control)	± 2.43	± 1.61 ^a	± 0.68	± 0.06	± 0.013
2	31.86	39.69	11.09	0.87	0.078 ± 0.085^{d}
(Dexa)	± 1.99	± 1.81	± 1.15	± 0.1	
3	32.66	37.42	10.59	0.85	0.080
(Beta)	± 1.78	± 1.71 ^b	± 0.96	± 0.07	± 0.045
4	32.06	40.89	12.38	1.05	0.085
(Dexa+PTH)	± 1.78	± 2.36	± 1.25°	±.0.11	± 0.01°
5	31.89	39.32	11.76	0.98	0.082
(Beta+PTH)	± 1.95	± 1.39	± 0.68	± 0.12	± 0.05

a: 2 ,4 ,5 p<0.05, b: 4 p<0.05 c: 1 ,3 p<0.05, d: 1 ,4 ,5 p<0.06 e: 2 ,3 p<0.05

BMC :Bone Mineral Content BMD : Bone Mineral Density

BMD




Figure 1.

2. CFU-Fs ALP






Figure 3. CFU-Fs ALP




Fig 4. (von Kossa stain)

```
Dexamethasone 2
                                (trabecualr bone)
   가
                                         5
       가
                                 . (Fig 5).
              Fig 5.
                secondary spongiosa , H&E stain, ×100)
  (
A: 1 (Control) B: 2 (Dexa) C: 3 (Beta)
D: 4
      (Dexa + PTH) E : 5 (Beta + PTH)
```

2.

	Cor por(%)	CCW [®]	TBV(%)	MTPT §
1 (control)	99.3	422.1	20.2	86.97
2 (Dexa)	98.3	424.6	14.9	76.65
3 (Beta)	96.9	427.2	18.8	84.72
4 (Dexa+PTH)	94.3	506.8	31.3	131.67
5 (Beta +PTH)	93.9	482.7	28.7	120.76

Cor por(cortical porosity), CCW(corrected cortical width) TBV(trabecualr bone volume), MTPT(mean trabecular plate thickness)

@ CCW : pixel(1 pixel =4.92 10^{-5} cm²)

§ MTPT :pixel(1 pixel =68 μ m)

	IV.			
	,			가
, 1 가	가	가 ,	,	6
progesterone , estrogen	가	, 1940	Hens	
(antianaphylaxis)			,	
	가 .			
가 Lane	¹⁹ , Turner 가		. 22	,
	가			
· 가 6	, dexamethasone	betamethaso 가	one	
(prednisolone	2.5 mg/kg)		,	
,) betamethasone	(3) ALP	가 dexamethaso	ne	(2

dexamethasone

. CFU-Fs

, 2

가

dexamethsone(2)

betamethasone(3)

CFU-Fs

```
dexamethasone
                                                    CFU-Fs
              ALP
                                                         , ALP
                 가 betamethasone
                                                      가
                            , dexamethasone
                                             betamethasone
                        가
dexamethasone
   , CFU-Fs
                       가가
(arrest)
                                                  가
                                                          (self
renewal) dexamethasone
                                                    Manolagus<sup>28</sup>,
Welsh<sup>29</sup>
          in vitro
                                                      가
                                                , in vitro
                                                     in vivo
                                           가
                                                       in vivo
            가
                         가 ALP
                                                 가
                                                      가
                           가
                                  ALP
                                                           가
dexamethasone
                                      betamethasone
     (5)
           Jilka
 가
                            12-13
                                       ALP
            가
                  가
           가
                                         dexamethasone
                         가
                              dexamethasone
           가
                                              가
                        . Calvil
```

, 가

.

V.

7-8

		betamethasone	dexamethasone	32
1.		dexameth	nasone	
2.	dexamethasone ALP			
3.	가	가 , ALP		
	devamethasone			

. 가

- 1. Buttgerit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998;41:761-767.
- 2. Buttgerit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: A novel glucocorticoid hierarchy. Biochem Pharmacol 1999;58:363-368.
- 3. Berger C.E.M, Horrocks BR, Datta HK. Direct non-genomic effect of steroid hormones on superoxide anion generation in the bone resorbing osteoclasts. Mol Cell Endocrinol 1999;149:53-59.
- 4. Sanden S, Tripmacher R, Weltrich R. Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rhematic diseases. J Rheumatol 2000;27:1265-1270.
- 5. Dempster D. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137-141.
- 6. Reid IR. Pathogenesis and treatment of steroid osteoporosis; Clin Endocrinol 1989;30:83-103.
- 7. Chyun YS, Kream BE, Raisz LG. Cortisol decreases bone formation by inhibiting periosteal cell proliferation. Endocrinology 1984;114:477-480.
- 8. Weinstein RS, Jilka RL, Parfitt MF. Inhibition of osteoporosis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids; Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-282.
- 9. Fitzpatrick LA. Glucocorticoid-induced osteoporosis. Osteoporosis Int 1994;202-226.
- 10. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-268.
- 11. Cortet B, Flipo RM, Blanckaert F. Evaluation of bone mineral density in patients with rheumatoid arthritis: Influence of disease activity and glucocorticoid therapy. Revue Du Rhumatisme 1997;64:451-458.
- 12. Jilka RL, Weinstein RS, K. Takahashi. Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 1996;97:1732-1740.
- 13. Jilka RL, Weinstein RS, Bellido T. Osteoblast programmed cell death(apoptosis): modulation by growth factors and cytokines. J

- Bone Miner Res 1998;13:793-802.
- 14. Aloia JF, Vaswani A, Neunier PJ. Coherence treatment of postmenopausal osteoporosis with growth hormone and calcitonin. Calcif Tissue Int 1987;40:253-259.
- 15. Aloia JF, Vaswani A, Kapoor A. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 1985;34:124-128.
- 16. Eastell R, Reid DM, Compstone J. A UK consensus group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-292.
- 17. Adachi JD, Bensen WG, Brown J. Intermittent etidronate therapy to prevent glucocorticoid-induced osteoporosis. N Engl J Med 1997;337: 382-387.
- 18. Reginster JY, Henrotin Y, Gosset C. Promising new agents in osteoporosis. Drugs RD 1999;1:195-201.
- 19. Lane NE, Sanchez S, Modin GW. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 1998;102:1627-1633.
- 20. Wunsch H. Parathyroid hormone may reverse corticosteroid bone effects. Lancet1998;352:1362.
- 21. Manolagas SC, Jilka RL, Weinstein RS. Parathyroid hormone and corticosteroid-induced osteoporosis. Lancet 1998;352:1940.
- 22. Turner RT, Evans GL, Cavolina JM. Programmed administration of parathyroid hormone increases bone formation and reduces bone loss in hindlimb-unloaded ovariectomized rats. Endocrinology 1998;139:4086-4091.
- 23. Jilka RL, Weinstein RS, Roberson P. PTH increases bone formation by postponing osteoblast apoptosis, not by increasing precursor proliferation. Bone 1998;23 Suppl:519.
- 24. Kroll MH. Parathyroid hormone temporal effects on bone formation and resorption. Bull Math Biol 2000;62:163-188.
- 25. King CS, Weir EC, Gundberg CW. Effects of continuous glucocorticoid infusion on bone metabolism in the rat. Calcif Tissue Int 1996;59:184-191.
- 26. Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000;356:87-88.
- 27. Pidebohant J. Methodological problems in bone fistomorphometry and its application in postmenopausal osteopotosis. Denish Medical Bulletin 1990;37:424-433.

- 28. Manolagas SC, Weistein RS. New developments in the pathogenesis and treatment of steroid induced osteoporosis. J Bone Miner Res 1999:14:1061-1066.
- 29. Walsh S, Jordan R, Jefferiss C, Srewart K, Beresford JN. High concentrations of dexamethasone suppress the proliferation but not the differentiation or further maturation of human osteoblast precursors in vitro: relevance to glucocorticoid-induced osteoporosis. Rheumatology 2001;40:74-83.
- 30. Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentiation affects cortical and trabecular bone. J Clin Invest 2001;107:277-286.

Abstract

The Effects of Recombinant Human Parathyroid Hormone
[rhPTH(1-84)] on Bone Change Induced by Glucocorticoids
with Different Action Mechanisms
in Mice

Seung Hee Choi

Division of Medical Sciences
The Graduate School, Yonsei University

(Directed by Professor Sung-Kil Lim)

The long-term use of steroids in treating patients with various diseases have been increasing, and the side effects of steroids, especially osteoporosis becomes a serious problem. Defects in bone formation, which cause significant bone loss, is a pathognomonic findings in steroid induced osteoporosis. Trabecular bone is affected more markedly than cortical bone. Many methods, such as replacement of calcium and active form Vit D, fluroride or anabolic steroids, bisphosphanates, low dose PTH administration, etc, were tried for the treatment. But, there was no clear consensus about treatment and prevention guidelines. Variable steroids have been known for their classical or genomic activity via glucocorticoid-

responsive elements on genomic DNA. There is no doubt that the therapeutic effects of glucocorticoids are mostly receptor-mediated. However, in recently, there is growing evidence that there is also non-genomic activity of glucocorticoids, via cytosolic receptor or via non-specific physicochemical activity. Therefore, It is necessary to verify a clinical significance of non-genomic action of glucocorticoid on bone.

In this experiment, we tried to find whether there was difference of genomic and non-genomic action in changes of mouse bones. We also tried to find the impact of combining human parathyroid hormone, which facilitates bone formation, on changes of bone induced by steroids with different mechanisms. We used 7-8 weeks old male mouse, which had maximal bone density at this stage. For the steroid, we have chosen dexamethasone and betamethasone. They have the same genomic action but have a 6-fold difference for non-genomic action. The bone density was measured under anesthetic condition and then changes of bone was analyzed by QDR 4500A(Hologic, Waltham, MA,USA). They were divided into 5 groups as; group 1: control, group 2: dexamethasone for 32 days, group 3: betamethasone for 32 days, group 4: dexamethasone and rhPTH(1-84) for 32 days.

- In group 2, although the average weight was increased, the bone mineral density was decreased significantly, compared to other groups. The bone density reduction was not significant in group 3.
- 2. Such reduction of the bone density tended to be improved with human parathyroid hormone applied, particularly in group 4.
- 3. Comparision of the mesenchymal cell indicator, CFU-Fs colony, and the pre-osteoblast segmentation indicator, ALP (alkaline phosphatase) positive colony, suggested that in group 2, there was a marked reduction in the number of ALP positive colony while no change in CFU-Fs colony.
- 4. The number of the ALP positive colony increased significantly in group 4.
- 5. von Kossa stain, which shows mineralization, the late indicator of the differentiation of osteoblast, was decreased in group 2 and increased in group 4 and 5.
- 6. Histomorphometrical study demonstrated that the volume and thickness of the trabecular bone decreased in group 2 and increased in group 4 and 5.

From the above results, we have shown that a long-term treatment

with dexamethasone, which contains a strong non-genomic action, brought up marked reduction in the bone mineral density, compared to betamathasone treatment. Reduction of bone mineral density might be due to inhibition of differentiation from mesenchymal cell into osteoblast lineage, based on both the numbers of ALP positive colonies for early osteoblast and mineralization.

These findings suggested that the accumulation of the non-genomic action of glucocorticoids has a greater impact on bone than genomic action in vivo. Injecting human parathyroid hormone has successfully inhibited the loss of bone density by dexamethasone.

In conclusion, for the use of steroid in the future, non-genomic action for defects of bone formation in steroid induced osteoporosis should be considered, and the combined administration of parathyroid hormones might play an important role for prevention of bone loss.